Related Experiment Video
Updated: Mar 14, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.7K
Apixaban: A Review in Venous Thromboembolism
Sarah L Greig1, Karly P Garnock-Jones2
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Drugs
|September 23, 2016
Summary
Apixaban effectively treats and prevents venous thromboembolism (VTE) with a favorable safety profile. This direct factor Xa inhibitor offers a valuable alternative for VTE management, demonstrating non-inferiority and improved safety in clinical trials.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Apixaban is an oral, direct factor Xa inhibitor for venous thromboembolism (VTE) treatment and prevention.
- Direct oral anticoagulants (DOACs) like apixaban offer predictable pharmacokinetics without routine monitoring.
Purpose of the Study:
- To evaluate the efficacy and safety of apixaban in the treatment and secondary prevention of VTE.
- To compare apixaban with enoxaparin/warfarin and placebo in large phase III trials.
Main Methods:
- Phase III trials (AMPLIFY, AMPLIFY-EXT, AMPLIFY-J) assessed apixaban's efficacy and safety in adult VTE patients.
- Comparisons included enoxaparin/warfarin for acute VTE treatment and placebo for extended prevention.
- Bleeding risk (major and clinically relevant nonmajor) was a key safety endpoint.
Main Results:
- Apixaban was non-inferior to enoxaparin/warfarin for acute VTE treatment (AMPLIFY).
- Apixaban was more effective than placebo in preventing recurrent VTE or all-cause mortality (AMPLIFY-EXT).
- Apixaban demonstrated a significantly lower risk of major or clinically relevant nonmajor bleeding compared to enoxaparin/warfarin and unfractionated heparin plus warfarin.
Conclusions:
- Apixaban is an effective and safe therapeutic option for managing adults with VTE.
- Its predictable profile and favorable bleeding risk make it a valuable alternative to traditional anticoagulants.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:30Venous Thrombosis I: Introduction
622
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
622
01:30Venous Thrombosis IV: Nursing Management
354
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
354
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
420
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
420